36 results
10-Q
2024 Q1
EX-10.3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Quarterly report
4:06pm
service to Company.
Proprietary Information. Executive has, and will continue to have, access to information of the Company that the Company
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:49pm
.
Expanded Access
Expanded access, sometimes called “compassionate use,” is the use of investigational products outside of controlled clinical trials … treatment options. FDA regulations allow access to investigational products under an IND by the sponsor or the treating physician for treatment purposes
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:45pm
.
Expanded Access
Expanded access, sometimes called “compassionate use,” is the use of investigational products outside of controlled clinical trials … treatment options. FDA regulations allow access to investigational products under an IND by the sponsor or the treating physician for treatment purposes
10-K
2023 FY
EX-19.1
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Annual report
4:48pm
significant disruption in the Company’s operations or loss, potential loss, breach, or unauthorized access of its property or assets, whether at its
10-K
2023 FY
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Annual report
4:48pm
.
Expanded Access
Expanded access, sometimes called “compassionate use,” is the use of investigational products outside of controlled clinical trials … options. FDA regulations allow access to investigational products under an IND by the sponsor or the treating physician for treatment purposes
8-K
EX-1.1
5ftsh1n0
22 Feb 24
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
4:05pm
8-K
EX-3.2
658l1 uybn
22 Feb 24
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
4:05pm
424B4
rbd4if8cgp 2vkyu4
20 Feb 24
Prospectus supplement with pricing info
5:30pm
424B4
q1rhxdb0t ylmnr
20 Feb 24
Prospectus supplement with pricing info
5:28pm